ONCOlog Medical receives large order for the PatLog system from clinic in Prague

Press release 
August 3, 2009	


ONCOlog Medical receives large order for the PatLog system from clinic in Prague

LinkMed's portfolio company ONCOlog Medical has received an order through its
partner IBA (Ion Beam Applications S.A.) for its PatLog® system from the Proton
Radiotherapy Centre in Prague, Czech Republic. The Proton Center will have four
treatment rooms equipped with the PatLog® systems for out-of-treatment room set
up. The order value is SEK 11 million.

The choice of PatLog® is a result of a successful cooperation between IBA and
ONCOlog Medical which has resulted in the first ongoing installation of a full
PatLog® system in Essen, Germany. 

“This order is a strategic market proof of our novel PatLog concept for better
and more cost efficient radiotherapy, and will have big importance for our
company´s success on the global radiotherapy market”, says Hans Dahlin, CEO of
ONCOlog Medical.  

The novel PatLog® approach of out-of-treatment room set up and smooth
transportation of the patient between different imaging devices and treatment
rooms, will highly improve the patient throughput in large radiotherapy clinics,
at the same time as the treatment accuracy, patient comfort and clinical
efficiency will be better.


About ONCOlog Medical
ONCOlog Medical is dedicated to innovative solutions in Radiation Therapy. The
company mission is to bring Better Radiotherapy to More People by improved
Accuracy, Comfort and Efficiency in Cancer care. The company was founded in 2002
and is owned by SLS Invest, LinkMed AB and the founders. Read more about ONCOlog
Medical at www.oncologmedical.com

LinkMed owns 40.4 percent of ONCOlog Medical.

For more information contact: 
Lars Martin, VP Senior Venture Manager LinkMed AB, tel: +46 706 360219
Hans Dahlin, CEO ONCOlog Medical, tel +46 18 19 45 63

Visit LinkMed's website: www.linkmed.se


LinkMed develops life science companies in collaboration with innovators and
other financiers. By contributing management expertise and capital, LinkMed has
created a portfolio of twelve companies, four in drug development and
biotechnology and eight in diagnostics and medical technology. LinkMed is listed
on the NASDAQ OMX Nordic Exchange in the Small Cap section (ticker: LMED).